Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs).
The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site.
Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain.
The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19.Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 21 | -0.04 Increased by +63.64% | -0.20 Increased by +80.00% |
| May 14, 21 | -0.08 Increased by +20.00% | -0.17 Increased by +52.01% |
| Feb 4, 21 | -0.25 Increased by +5.50% | -0.15 Decreased by -62.56% |
| Oct 27, 20 | -0.19 Decreased by -6.06% | -0.13 Decreased by -46.72% |
| Aug 5, 20 | -0.11 Increased by +54.84% | -0.09 Decreased by -22.22% |
| May 13, 20 | -0.10 Increased by +12.13% | -0.11 Increased by +9.09% |
| Feb 10, 20 | -0.26 Increased by +22.30% | -0.14 Decreased by -84.02% |
| Oct 22, 19 | -0.18 Increased by +19.78% | -0.26 Increased by +29.50% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 21 | 160.18 M Increased by +1.26 K% | -75.51 M Increased by +68.86% | Decreased by -47.14% Increased by +97.71% |
| Mar 31, 21 | 37.62 M Increased by +214.16% | -218.24 M Decreased by -1.70% | Decreased by -580.14% Increased by +67.63% |
| Dec 31, 20 | 12.08 M Increased by +1.15% | -292.59 M Decreased by -6.04% | Decreased by -2.42 K% Decreased by -4.83% |
| Sep 30, 20 | 66.09 M Increased by +250.88% | -233.69 M Decreased by -30.98% | Decreased by -353.57% Increased by +62.67% |
| Jun 30, 20 | 11.78 M Decreased by -42.81% | -242.44 M Decreased by -0.40% | Decreased by -2.06 K% Decreased by -75.56% |
| Mar 31, 20 | 11.97 M Decreased by -92.41% | -214.59 M Decreased by -92.13% | Decreased by -1.79 K% Decreased by -2.43 K% |
| Dec 31, 19 | 11.95 M Decreased by -31.27% | -275.94 M Increased by +10.03% | Decreased by -2.31 K% Decreased by -30.91% |
| Sep 30, 19 | 18.84 M Increased by +23.29% | -178.43 M Increased by +8.97% | Decreased by -947.20% Increased by +26.16% |